|
1 pahu (10 Vials)
| Ka nui: | |
|---|---|
▎ Hoʻonohonoho Sel
Puna: PubChem |
Kaʻina: TKPRPGP Hui Molekala: C 33H 57N 11O9 Kaumaha Molekala: 751.9 g/mol Helu CAS: 129954-34-3 PubChem CID: 11765600 Nā huaʻōlelo like: Sel |
▎ Sel Research
He aha ke kumu noiʻi o Sel?
ʻO ka Neuroadaptation a me ka Pūnaehana Opioid Endogenous:
Hoʻokomo ʻia ka ʻōnaehana opioid endogenous i ke kaʻina neuroadaptation i hana ʻia e nā opioids exogenous. ʻO Sel, kahi anxiolytic synthesized e pili ana i ka peptide tuftsin regulatory, hiki ke kāohi i ka hana o nā enzymes enkephalin-degrading, pēlā e hoʻonui ai i ke kiʻekiʻe o ka leucine enkephalin i ka plasma (Nadorova AV, 2022). Hōʻike kēia i hiki iā Sel ke hoʻokō i kāna mau hopena ma ka hoʻoponopono ʻana i ka ʻōnaehana opioid endogenous.
ʻO ka hopohopo a me nā maʻi naʻau kekahi o nā pilikia olakino maʻamau i ka honua. Hoʻohana nui ʻia nā lāʻau lapaʻau anxiolytic maʻamau i ka hoʻoponopono pharmacological o ka hana o ka ʻōnaehana GABA receptor o ka lolo. Eia nō naʻe, ʻo ia mau lāʻau lapaʻau e loaʻa i kahi ʻano o nā pilikia lapaʻau e like me ka hilinaʻi a me ka hoʻomanaʻo hoʻomanaʻo (Vyunova TV, 2018). Ke hoʻonui nei ka ʻike i ka hana o nā neuropeptides a me nā lipid bioactive i ka pathophysiology o ke ʻano a me nā maʻi hopohopo. Hōʻike ka heptapeptide Sel i nā hopena anxiolytic a me nā hopena nootropic lōʻihi (Vyunova TV, 2018).
He aha ke ʻano o ka hana a Sel?
He aha ke ʻano o ka hana a Sel i ka hopohopo a me nā pilikia o ke ʻano?
Hoʻoponopono i ka GABA Receptor System:
ʻO ka hopohopo a me nā maʻi naʻau ka pilikia maʻamau o ka noʻonoʻo ma ka honua. Hoʻohana pinepine ʻia nā lāʻau lapaʻau anxiolytic maʻamau i kā lākou hopena ma ka hoʻoponopono ʻana i ka hana o ka ʻōnaehana receptor GABA i ka lolo, akā loaʻa pinepine lākou i nā pilikia e like me ka hilinaʻi a me ka hoʻomanaʻo. Ua ʻike nā haʻawina ʻo ka heptapeptide Sel (Thr-Lys-Pro-Arg-Pro-Gly-Pro) he hopena therapeutic i ka hopohopo a me nā maʻi naʻau. Ua hōʻike nā ʻano loiloi Radioligand-receptor e pili ana ʻo Sel i ka [3H] GABA paʻa ma ke ʻano he modulator allosteric maikaʻi. ʻO ka hana hui pū a Sel me kekahi mau benzodiazepines e hoʻoponopono pū i ka hana hoʻopaʻa [3H] GABA ma kahi ala kikoʻī. ʻAʻole hoʻohui kēia hopena a ʻokoʻa ka hoʻohana ʻana i kēlā me kēia mea wale nō. Hiki iā Sel ke pale i nā hana hoʻoponopono o ka diazepam a me ka olanzapine. ʻOkoʻa kona kahua paʻa i nā lāʻau lapaʻau, akā hiki ke uhi ʻia kekahi hapa [1] . No laila ke manaʻo ʻia e pili ana kekahi o nā mīkini mole o ka hopena anxiolytic o Sel i ka subtype-selective concentration-dependent allosteric regulation o GABA receptors.
He aha ke ʻano o Sel i ka hoʻomaha ʻana i ka analgesia i hoʻoulu ʻia e ka morphine?
Kāohi i ka hoʻihoʻi ʻana o Morphine:
Ua hōʻike ʻia kekahi mau haʻawina e hiki i ka mea peptide Sel ke hoʻonāwaliwali i ka hoʻihoʻi ʻana o nā ʻiole i ka morphine ma kekahi ʻano. No ka laʻana, i ka morphine withdrawal model induced by naloxone, hoʻokahi intraperitoneal injection of Sel (0.3mg/kg) hiki ke hoʻemi i ka huina helu helu o ka morphine withdrawal syndrome e 39.6%, e hoʻohaʻahaʻa loa i nā hōʻailona e like me ka convulsive reactions, ptosis, a me nā maʻi postural, a hoʻonui i ka tactile o ka morphine sensitivity threshold . Hōʻike kēia i hiki ke hoʻopili pololei ʻo Sel i ka hana analgesic o ka morphine ma o ka hoʻoponopono ʻana i ka hilinaʻi o ka ʻōnaehana nerve i ka morphine.
ʻO ka hopena analgesic Synergistic me ka Morphine:
I nā hoʻokolohua holoholona, ua ʻike nā mea noiʻi ua hōʻike ʻo Sel i kahi hopena analgesic synergistic i ka wā i hoʻohana ʻia me ka morphine. Hiki i ka Morphine ke hana i kekahi degere o ka analgesia ma kekahi ma'i, a 'oiai 'a'ole maopopo ka hopena analgesic o Sel iho, ke ho'ohana 'ia me ka morphine ma kahi kiko'ī (0.9mg/kg), hiki iā ia ke ho'onui i ka latency o ka pane o ka iole i ka ho'oulu wela, e ho'onui ana i ka hopena analgesic i ka 29.9% o ka hopena hiki loa (MBE) [3] . Hōʻike kēia i hiki iā Sel ke hoʻonui i ka hopena analgesic o ka morphine ma o kekahi ala.
Ke hana nei ma ka Enkephalin System:
Ma muli o ke aʻo ʻana i nā hopena physiological o Sel a me kāna mau ʻāpana, ua manaʻo ʻia e hana ʻo Sel ma ka pūnaewele o ke kaʻina cascade o nā peptides a me nā mea hoʻolaha ma o enkephalin. ʻO Enkephalin kahi ʻano o ka peptide opioid endogenous a he hana koʻikoʻi i ka hoʻoponopono ʻeha. Hiki iā Sel ke hoʻopili i ka hopena analgesic o ka morphine ma o ka hoʻoponopono ʻana i ka hana o nā enkephalin-degrading enzymes a me ka hoʻonui ʻana i ke kiʻekiʻe o ka leucine enkephalin i ka plasma [4].
Nā hopena o Sel (0.3 mg / kg) i ka ʻike ʻana i ka mea hou i nā ʻiole i hoʻopaʻa ʻia i ka waiʻona ikaika.
Puna:PubMed [7]
He aha ke kumu kūpono o Sel i ka mālama ʻana i ka nāwaliwali o ka maʻi post-COVID?
Ma muli o nā hopena Immunomodulatory:
Ke noʻonoʻo nei i ke kuleana koʻikoʻi o nā maʻi immune i ka pathogenesis o COVID-19, nā lāʻau lapaʻau me nā hopena immunomodulatory me he mea lā e hoʻohiki nei i ka mālama ʻana i ka post-COVID syndrome. ʻO Sel kahi lāʻau peptide i hana ʻia ma muli o ka immunomodulator tafcin. I ka mālama ʻana i ka maʻi post-COVID, hiki iā Sel ke hōʻoluʻolu i nā hōʻailona nāwaliwali ma o ka hoʻoponopono ʻana i ka ʻōnaehana pale a me ka hoʻoponopono ʻana i ka hana ʻino. No ka laʻana, he hana pololei paha ʻo Sel i ka pili kino a i ʻole e hana pololei ʻole ma ka hōʻemi ʻana i ka pane post-stress, a laila mālama i ke kūlana maʻamau o ka hana immune [5].
Anxiolytic a me ka hoʻomaikaʻi ʻana i nā maʻi ʻino:
I ka maʻi post-COVID, ʻike pinepine nā mea maʻi i nā maʻi ʻeha e like me ka hopohopo a me ke kaumaha, i hele pū ʻia me ka nāwaliwali a me ka emi ʻana o ka hana. Ua hōʻike nā haʻawina e hiki iā Sel ke hoʻomaha i nā hōʻailona o ka hopohopo a me ke kaumaha i ka wā o ka mālama ʻana. Pili paha kāna hana i ka hoʻoponopono ʻana o Sel i ka ʻōnaehana neurotransmitter i ka lolo. No ka laʻana, hiki iā Sel ke hana ma ke ʻano he modulator allosteric maikaʻi e hoʻopili i ka [3H] GABA paʻa, a laila e hoʻoponopono i ka hana o ka ʻōnaehana receptor GABA a hoʻokō i kahi hopena anxiolytic [1].
Ka hopena neuroprotective:
Ma ke aʻoʻana, ua māheleʻia nā maʻi iʻelua hui. Hoʻokahi hui i hoʻohana i kahi neuroprotective complex (cholitilin, mexidol, milgamma) a me Sel, a ʻo ka hui ʻē aʻe i hoʻohana wale i ka neuroprotective complex. Ua hōʻike nā hopena i nā mea maʻi e hoʻohana ana iā Sel i nā hopena maikaʻi aʻe e pili ana i ka nāwaliwali a hoʻemi i ka hana noʻonoʻo. Hōʻike kēia i hiki iā Sel ke hana synergistically me ka neuroprotective complex e hana i kahi hopena neuroprotective, pēlā e hoʻomaikaʻi ai i nā hōʻailona nāwaliwali o nā maʻi [5].
Ka hopena antiviral:
Ua ʻike nā haʻawina he waiwai antiviral ʻo Sel i nā maʻi influenza hoʻokolohua. ʻOiai ʻaʻohe hōʻike pololei i kēia manawa he hopena antiviral ʻo Sel i ka maʻi COVID-19, i hāʻawi ʻia i kāna hana i nā maʻi maʻi maʻi influenza, loaʻa paha iā Sel kekahi hopena i ka maʻi COVID-19 ma o kekahi ʻano hana, no laila ke kōkua nei i ka mālama ʻana i ka nāwaliwali o ka maʻi post-COVID. No ka laʻana, i loko o nā haʻawina in vivo, ua hoʻokomo ʻo Sel i ka hōʻike gene o interferon-α (IFN-α), hiki ke kōkua i ka hoʻonui ʻana i ka mana antiviral o ke kino [6].
He aha nā hopena o Sel?
Anxiolytic a me ka hoʻomaikaʻi ʻana i nā maʻi ʻino:
I ka maʻi post-COVID, ʻike pinepine nā mea maʻi i nā maʻi ʻeha e like me ka hopohopo a me ke kaumaha, i hele pū ʻia me ka nāwaliwali a me ka emi ʻana o ka hana. Ua hōʻike nā haʻawina e hiki iā Sel ke hoʻomaha i nā hōʻailona o ka hopohopo a me ke kaumaha i ka wā o ka mālama ʻana. Pili paha kāna hana i ka hoʻoponopono ʻana o Sel i ka ʻōnaehana neurotransmitter i ka lolo. No ka laʻana, hiki iā Sel ke hana ma ke ʻano he modulator allosteric maikaʻi e hoʻopili i ka [3H] GABA paʻa, a laila e hoʻoponopono i ka hana o ka ʻōnaehana receptor GABA a hoʻokō i kahi hopena anxiolytic [1].
Ka hopena neuroprotective:
Ma ke aʻoʻana, ua māheleʻia nā maʻi iʻelua hui. Hoʻokahi hui i hoʻohana i kahi neuroprotective complex (cholitilin, mexidol, milgamma) a me Sel, a ʻo ka hui ʻē aʻe i hoʻohana wale i ka neuroprotective complex. Ua hōʻike nā hopena i nā mea maʻi e hoʻohana ana iā Sel i nā hopena maikaʻi aʻe e pili ana i ka nāwaliwali a hoʻemi i ka hana noʻonoʻo. Hōʻike kēia i hiki iā Sel ke hana synergistically me ka neuroprotective complex e hana i kahi hopena neuroprotective, pēlā e hoʻomaikaʻi ai i nā hōʻailona nāwaliwali o nā maʻi [5].
Hoʻopau i ka analgesia i hoʻokomo ʻia e Morphine:
Ua hōʻike ʻia kekahi mau haʻawina ʻo Sel, kahi anxiolytic synthesized e pili ana i ka regulatory peptide tuftsin, he hopena i ka analgesia i hoʻokomo ʻia i ka morphine i nā ʻano holoholona. No ka laʻana, inā he 3.0mg/kg ka nui o ka morphine (intraperitoneal injection), hiki iā ia ke hana i ka antinociception, me ka hopena hiki loa (MBE) o 9%. ʻOiai ʻaʻohe hopena antinociceptive o ka Sel o 0.9mg/kg, i ka wā i mālama mua ʻia me ka morphine, hiki iā ia ke hoʻonui i ka manawa o ka latent reaction a hoʻoulu i kahi hopena antinociceptive o 29.9% MBE [3].
E hoʻohaʻahaʻa i nā hōʻailona aversive o ka wehe ʻana o Morphine:
Ua aʻo ʻia ka hana o ka peptide tuftsin analog Sel i kahi hoʻohālike hoʻihoʻi morphine i hoʻokomo ʻia e naloxone. ʻO kahi hoʻokahi intraperitoneal injection o Sel ma kahi maʻi anxiolytic o 0.3mg/kg hiki ke hōʻemi i ka huina o ka morphine withdrawal syndrome e 39.6%, ʻoi loa (p<0.0001) e hoʻēmi i nā hopena convulsive, ptosis, a me nā maʻi postural, a hoʻonui i ka paepae sensitivity tactile me nā manawa hilinaʻi morphine9. I ka manawa like, he haʻahaʻa iki ʻo Sel i ka diazepam ma kahi ʻano o 2mg / kg e pili ana i ka hana pharmacological (e hoʻemi ana i ka helu helu helu o ka morphine withdrawal syndrome e 49.3% a hoʻonui i ka paepae sensitivity e 13 mau manawa). No laila, e like me ka diazepam, hiki iā Sel ke hoʻohaʻahaʻa i nā hōʻailona aversive o ka wehe ʻana o ka morphine i ka hilinaʻi opioid i nā ʻiole [2].
Kāohi ʻana i ka pōʻino o ka hoʻomanaʻo ʻana i ka ethanol:
I nā ʻiole i loaʻa i ka 10% ethanol ma ko lākou kumu wai hoʻokahi a hiki i 30 mau pule, ua noiʻi ʻia nā hopena o Sel, kahi lāʻau anxiolytic peptide-based synthesized mai ka endogenous peptide tuftsin, ma ka hōʻino hoʻomanaʻo a me nā pae neurotrophic i loaʻa i ka lolo (BDNF). Ma nā hoʻāʻo ʻike ʻike mea, ua hōʻike ʻo Sel i nā hopena hoʻonui naʻau i nā ʻiole 9 mau mahina ʻaʻole i ʻike ʻia i ka ethanol a pale i ka hoʻomohala ʻana o ka hoʻomanaʻo ʻana i ka ethanol a me nā hemahema o ka nānā ʻana i ka wā o ka haʻalele ʻana i ka waiʻona. Ua hōʻike ʻia nā hoʻokolohua in vitro hiki iā Sel ke kāohi i ka piʻi ʻana o ka ethanol i nā pae BDNF ma ka hippocampus a me ka cortex prefrontal. Mai ka mea i luna aʻe, hiki ke hoʻoholo ʻia he hopena maikaʻi kēia synaptogenic agent i ka hoʻomanaʻo ʻana i ka makahiki e pili ana i ka hilinaʻi ʻana i ka waiʻona mau, a hōʻoia i ka pili ʻana o nā ʻano neurotrophic pili i ka BDNF i ka hana o ka hana a Sel [7].
Ka mālama ʻana i ka Post-COVID-19 Syndrome:
Loaʻa ka maʻi post-COVID-19 ma hope o ka maʻi COVID-19 a hiki ke ʻike ʻia i nā hihia o ka maʻi ʻeha a i ʻole asymptomatic. ʻO nā hōʻailona maʻamau o ka maʻi alahaka ʻo ka luhi a me ka emi ʻana o ka hana, a ukali ʻia e nā hemahema o ka naʻau. Hāʻawi ʻia i ka hana koʻikoʻi o ka immune dysregulation i ka pathogenesis o COVID-19, nā lāʻau immunomodulatory me nā hopena immune-modulating pololei a i ʻole nā mea e mālama pono ʻole i ka hana kūlohelohe ma o ka hōʻemi ʻana i nā pane post-stress paʻa i ka ʻōlelo hoʻohiki therapeutic.
ʻO Sel kahi lāʻau peptide i hoʻomohala ʻia ma muli o ka immunomodulator tafcin, kahi kūpono i ka mālama ʻana i nā neuroses a me nā maʻi neurosis-like. Ke hoʻohana ʻia ma kahi ʻano o 2-3 hāʻule i ʻehā mau manawa i ka lā no 30 mau lā, loaʻa ka hopena therapeutic maikaʻi o Sel i nā maʻi me ka luhi a me ka naʻau. Hiki ke ʻike ʻia nā hōʻailona o ka hopohopo a me ke kaumaha [5].
Hoʻoponopono i nā maʻi noʻonoʻo a me ka naʻau i nā poʻe maʻi me ka dermatitis atopic: Ua kālailai ʻia kahi noiʻi i nā maʻi cognitive a me ka naʻau ma 65 mau maʻi me ka dermatitis atopic (AD) a hoʻokaʻawale i nā mea maʻi i ʻelua pūʻulu hoʻohālikelike.
ʻO ka hui mua o nā maʻi i loaʻa i ka lāʻau lapaʻau maʻamau no ka atopic dermatitis (BT), aʻo ka lua o ka hui i loaʻa ka hui pū ʻana o serank a me BT ma o intranasal administration (S + BT), lawelawe ʻia ʻekolu manawa i kēlā me kēia lā, me ʻelua kulu i hoʻokomo ʻia i loko o kēlā me kēia puka ihu no kēlā me kēia dosis, no ka huina o 14 mau lā. ʻO ka hui hoʻomalu he 30 mau kānaka olakino. ʻO ka hopohopo pilikino (LT), ka hopohopo reactive (RT), nā pae yohimbine, nā pae koko β-endorphin, a me ka maikaʻi o ke ola (QOL) i loiloi ʻia ma mua o ka mālama ʻana a me nā lā 30 ma hope o ka hoʻomaka ʻana o ka mālama ʻana.
Ua hōʻike nā hualoaʻa o ka haʻawina he 4.2 mau manawa kiʻekiʻe ma mua o ka poʻe i loko o ka pūʻulu hoʻomalu, ʻo 3 mau manawa kiʻekiʻe ka pae o LT, a ʻo nā pae yekhtumia he 18 mau manawa kiʻekiʻe. Ma ka hui BT, ua emi iho ka RT ma 1.4 manawa a ua emi iho ka LT ma 1.3 manawa 30 mau lā ma hope o ka hoʻomaka ʻana o ka mālama ʻana. I loko o ka hui C+BT, ua like like ka emi ʻana o LT a me RT, ʻelua ma 2.4 manawa.
ʻAʻohe hoʻololi koʻikoʻi i nā hōʻailona yekutumia a i ʻole nā pae β-endorphin i ke koko o nā maʻi ma ka hui BT. Ma ka hui S + BT, ua ho'ēmiʻia nā maʻi naʻau Alexis i nā manawa 1.2, a ua hoʻonuiʻia nā pae β-endorphin i loko o ke koko e 1.9 manawa. ʻO ka maikaʻi o ka helu ola o nā maʻi ma ka hui BT i emi iho i ka 1.2 manawa 30 mau lā ma hope o ka hoʻomaka ʻana o ka mālama ʻana, ʻoiai ʻo ka poʻe maʻi i ka hui S + BT i emi iho i ka manawa 1.7. ʻO ka hopena, ʻo nā kiʻekiʻe kiʻekiʻe o ka hopohopo pilikino, ka hopohopo reactive, a me ka yekhtumia i nā maʻi maʻi AD e hōʻemi i ko lākou ola. ʻO ka hoʻohana ʻana i ka peptide Sel regulator i ka mālama piha ʻana i nā maʻi maʻi AD he hopena hoʻoponopono i nā pilikia o ka naʻau a me ka cognitive, e hoʻemi ana i nā pae o ka hopohopo pilikino, ka hopohopo reactive, a me ka yekhtumia, ka hoʻonui ʻana i nā pae o β-endorphin i loko o ke koko, a me ka hoʻomaikaʻi ʻana i ka maikaʻi o ke ola o nā maʻi [8].
I ka hopena, ma ke ʻano he lāʻau peptide synthetic i hoʻomohala ʻia e pili ana i ka clusterin peptide kūlohelohe, ua hōʻike ʻo Sel i ka hiki ke noi multi-dimensional i ka hana lapaʻau a me ka noiʻi. Aia kāna waiwai nui i ka hāʻawi ʻana i nā hopena hou no nā maʻi e like me nā maʻi hopohopo, nā pilikia pili i ke koʻikoʻi, ka hōʻino ʻana i ka hoʻomanaʻo, a me nā maʻi kūlohelohe ma o ka hoʻoponopono ʻana i ka ʻōnaehana neurotransmitter, hoʻonui i ka hana immune, a hoʻomaikaʻi i ka hana cognitive. Ua hōʻoia ʻia nā noiʻi maʻi e hiki iā Sel ke hōʻoluʻolu maikaʻi i nā hōʻailona o ka hopohopo a me ke kaumaha, hoʻomaikaʻi i ka nāwaliwali a me nā maʻi cognitive i ka post-COVID syndrome, a synergistically hoʻonui i ka hopena anti-inflammatory i ka mālama ʻana i ka dermatitis atopic. Ke hoʻohālikelike ʻia me nā lāʻau lapaʻau maʻamau, ʻoi aku ka liʻiliʻi o nā hopena ʻaoʻao, ʻoi aku ka lōʻihi o ka hana, a hōʻike i nā pono kūʻokoʻa ma nā kahua o ka analgesia, anti-addiction, a me neuroprotection.
No ka mea kakau
ʻO nā mea i ʻōlelo ʻia ma luna nei ua noiʻi ʻia, hoʻoponopono ʻia a hōʻuluʻulu ʻia e Cocer Peptides.
Mea kākau moʻolelo ʻepekema
ʻO Vyunova TV he neurochemist Lūkia, chemist, biologist, a me ka mea noiʻi. Ua hāʻawi nui ʻo ia i nā ʻāpana o ka biochemistry & molecular biology, chemistry, biophysics, pharmacology & pharmacy, a me ka physiology. Ua pili ʻo Vyunova me nā ʻoihana hanohano e like me ka National Research Center 'Kurchatov Institute' a me ka Russian Academy of Science. Ua alakaʻi pū ʻia ka noiʻi a Vyunova i kekahi mau patent, e hōʻike ana i kāna ala hou i nā pilikia ʻepekema. ʻO kona kūpaʻa i ka hoʻonui ʻana i ka ʻike ma kāna mau kula, ua lilo ʻo ia i mea i mahalo nui ʻia ma ke kaiāulu ʻepekema. Hoʻopaʻa ʻia ʻo Vyunova TV ma ka ʻōlelo kuhikuhi [1].
